Strauss Borrelli PLLC, a leading data breach law firm, is investigating Dendreon Pharmaceuticals, LLC (“Dendreon”) regarding its recent data breach. The Dendreon data breach involved sensitive protected health information belonging to an undetermined number of individuals.
ABOUT DENDREON PHARMACEUTICALS, LLC:
Dendreon is a commercial-stage biopharmaceutical company and end-to-end provider of manufacturing services for the cell therapy market based in California.2 Founded in 1992, Dendreon’s flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy to harness the innate benefits of personalized cellular treatment made from a patient’s own immune cells.2 Since its FDA-approval in 2010, nearly 40,000 men have been prescribed PROVENGE.2 Headquartered in Seal Beach, California, Dendreon has two additional locations in Georgia and Washington and employs over 500 individuals.
WHAT HAPPENED?
Recently, Dendreon was informed that its business partner, Cencora, Inc., and its Lash Group affiliate had experienced a data breach in which sensitive protected health information belonging to Dendreon customers in its systems may have been accessed and acquired. Through its investigation, Cencora determined that an unauthorized actor gained access to this sensitive information on February 21, 2024. On May 23, 2024, Cencora began notifying individuals whose information may have been impacted. The type of information potentially exposed includes:
- Name
- Date of birth
- Address
- Medical information (e.g., health diagnosis, and/or medications and prescriptions)
If you received a breach notification letter from Dendreon Pharmaceuticals, LLC, Cencora, Inc., or The Lash Group:
We would like to speak with you about your rights and potential legal remedies in response to this data breach. Please fill out the form, below, or contact us at 872.263.1100 or sam@straussborrelli.com.
